Intellia Therapeutics (NASDAQ:NTLA) Price Target Raised to $15.00

Intellia Therapeutics (NASDAQ:NTLA) had its target price upped by Wells Fargo & Company from $12.00 to $15.00 in a report issued on Tuesday morning,Benzinga reports. They currently have an equal weight rating on the stock.

NTLA has been the topic of several other reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Intellia Therapeutics in a report on Thursday, January 22nd. Evercore set a $8.00 price target on shares of Intellia Therapeutics and gave the stock an “in-line” rating in a research report on Tuesday, November 11th. Royal Bank Of Canada cut their price objective on shares of Intellia Therapeutics from $14.00 to $9.00 and set a “sector perform” rating on the stock in a report on Friday, November 7th. JonesTrading downgraded shares of Intellia Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, November 11th. Finally, Wolfe Research reaffirmed a “peer perform” rating on shares of Intellia Therapeutics in a research report on Wednesday, November 12th. Eleven investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $19.59.

Intellia Therapeutics Stock Down 4.8%

NTLA opened at $13.15 on Tuesday. The stock’s fifty day moving average is $12.25 and its two-hundred day moving average is $13.10. The company has a market capitalization of $1.55 billion, a P/E ratio of -3.43 and a beta of 2.10. Intellia Therapeutics has a 52 week low of $5.90 and a 52 week high of $28.25.

Intellia Therapeutics (NASDAQ:NTLA) last issued its earnings results on Thursday, February 26th. The company reported ($0.83) earnings per share for the quarter, topping the consensus estimate of ($0.99) by $0.16. The business had revenue of $23.02 million during the quarter, compared to analysts’ expectations of $12.17 million. Intellia Therapeutics had a negative return on equity of 56.81% and a negative net margin of 609.85%.The business’s revenue for the quarter was up 78.4% compared to the same quarter last year. During the same period in the prior year, the business earned ($1.27) EPS. Equities analysts anticipate that Intellia Therapeutics will post -5.07 earnings per share for the current year.

Insiders Place Their Bets

In other news, EVP Birgit C. Schultes sold 8,508 shares of the company’s stock in a transaction on Monday, January 5th. The stock was sold at an average price of $9.21, for a total transaction of $78,358.68. Following the transaction, the executive vice president directly owned 98,533 shares of the company’s stock, valued at approximately $907,488.93. This represents a 7.95% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP James Basta sold 10,397 shares of the firm’s stock in a transaction on Monday, January 5th. The stock was sold at an average price of $9.21, for a total value of $95,756.37. Following the completion of the sale, the executive vice president directly owned 101,528 shares of the company’s stock, valued at $935,072.88. The trade was a 9.29% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 53,051 shares of company stock valued at $488,600. 3.10% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Intellia Therapeutics

Large investors have recently modified their holdings of the business. Virtu Financial LLC purchased a new position in shares of Intellia Therapeutics in the 4th quarter valued at approximately $245,000. Invesco Ltd. increased its stake in Intellia Therapeutics by 5.8% during the 4th quarter. Invesco Ltd. now owns 433,290 shares of the company’s stock valued at $3,895,000 after purchasing an additional 23,870 shares in the last quarter. Axxcess Wealth Management LLC raised its holdings in shares of Intellia Therapeutics by 20.1% in the fourth quarter. Axxcess Wealth Management LLC now owns 21,399 shares of the company’s stock worth $192,000 after buying an additional 3,583 shares during the last quarter. Mercer Global Advisors Inc. ADV purchased a new position in shares of Intellia Therapeutics in the fourth quarter worth $90,000. Finally, XTX Topco Ltd acquired a new stake in shares of Intellia Therapeutics during the fourth quarter worth $402,000. Hedge funds and other institutional investors own 88.77% of the company’s stock.

Key Headlines Impacting Intellia Therapeutics

Here are the key news stories impacting Intellia Therapeutics this week:

• Positive Sentiment: FDA lifts clinical holds on a second gene‑therapy trial for Intellia — a material de‑risking event that restores clinical momentum for NTLA’s in‑vivo programs and was a direct catalyst for recent rallies. FDA’s lifting of clinical holds sends Intellia upwards
• Positive Sentiment: Multiple analyst upgrades and bullish notes — JonesTrading upgraded NTLA to Buy with a $29 target (large upside), and other firms (Leerink, Wells Fargo) issued bullish commentary that supports higher near‑term sentiment. JonesTrading upgrade / coverage summary
• Positive Sentiment: Royal Bank of Canada raised its price target to $15, reinforcing analyst support after the recent rebound. RBC boosts Intellia price target to $15
• Neutral Sentiment: HC Wainwright slightly trimmed near‑term EPS estimates but kept a Buy rating and a $30 target — a mixed signal (modest near‑term cost pressure acknowledged, long‑term conviction intact). HC Wainwright analyst note
• Neutral Sentiment: Valuation discussion: recent recovery has put NTLA back on investors’ radar but analysts note wide losses and heavy R&D spending; the stock’s rebound raises valuation questions for some investors. A Look At Intellia Therapeutics Valuation
• Negative Sentiment: Canaccord lowered expectations for NTLA — an analyst downgrade to forecasts that can weigh on near‑term sentiment and give holders a reason to take profits after the run‑up. Canaccord lowers expectations

About Intellia Therapeutics

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.